By IDSE News Staff
Most HIV patients achieved an undetectable viral load through 48 weeks after starting the single-tablet regimen (STR) of darunavir, cobicistat, emtricitabine and tenofovir alafenamide (D/C/F/TAF; Symtuza, Janssen) right after learning they were HIV-positive, according to results presented at the 2019 Annual American Conference for the Treatment of HIV in Miami.
The DIAMOND study evaluated the once-daily STR for the treatment of HIV-1 infection in adults who were enrolled within